Cytek Biosciences (NASDAQ: CTKB) CLO reports RSU vesting and tax share surrender

Rhea-AI Filing Summary

Cytek Biosciences, Inc. chief legal officer Valerie Barnett reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 1,346 restricted stock units were exercised into 1,346 shares of common stock at a stated price of $0.00 per share.

On the same date, 525 common shares at $4.20 per share were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations related to the vesting of this RSU award. After these transactions, Barnett directly held 116,462 shares of Cytek Biosciences common stock. The RSU award vests quarterly over four years, with an initial 4/48th tranche vesting on May 18, 2022, and 3/48th of the total shares vesting on each subsequent August 18, November 18, February 18, and May 18.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barnett Valerie

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		M		1,346	A	(1)	116,987	D
Common Stock	02/18/2026		F		525(2)	D	$4.2	116,462	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/18/2026		M			1,346	(3)	(3)	Common Stock	1,346	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

3. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

	/s/ Valerie Barnett	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CTKB’s chief legal officer report?

Cytek Biosciences’ chief legal officer reported RSU-related transactions. 1,346 restricted stock units converted into 1,346 common shares, and 525 shares were withheld and surrendered to cover tax obligations tied to the RSU vesting, leaving 116,462 shares directly held.

Did the CTKB insider buy or sell shares on the open market?

The Form 4 shows no open-market buy or sell. Shares were acquired through the exercise of 1,346 restricted stock units and 525 shares were surrendered back to Cytek Biosciences solely to satisfy tax withholding obligations from this vesting event.

How many CTKB shares does Valerie Barnett hold after these transactions?

Following the reported transactions, Valerie Barnett directly holds 116,462 shares of Cytek Biosciences common stock. This reflects the RSU conversion of 1,346 shares and the surrender of 525 shares to the company for tax withholding obligations.

What was the price used for the CTKB tax-withholding share surrender?

The tax-withholding disposition used a price of $4.20 per Cytek Biosciences share. A total of 525 common shares were withheld and surrendered back to the company to cover tax obligations that arose when the restricted stock units vested.

How do the CTKB restricted stock units vest over time?

The restricted stock unit award vests quarterly over four years. 4/48th of the total RSU shares vested on May 18, 2022, and 3/48th vests on each subsequent August 18, November 18, February 18, and May 18, until fully vested.

What does transaction code M mean in the CTKB Form 4?

Transaction code M indicates an exercise or conversion of a derivative security. Here, 1,346 Cytek Biosciences restricted stock units were converted into 1,346 common shares, reflecting vesting of the RSU award rather than an open-market purchase transaction.

What does transaction code F mean in this CTKB insider filing?

Transaction code F reflects shares surrendered to cover exercise price or taxes. In this case, 525 Cytek Biosciences common shares were withheld and given back to the company to satisfy tax withholding obligations tied to the vesting of the RSU award.